Tirzepatide and retatrutide are both incretin-based compounds studied for weight management, but they differ in regulatory status and in how many receptors they target. Tirzepatide, sold as Mounjaro and Zepbound, activates the GLP-1 and GIP receptors and is FDA-approved. Retatrutide adds a third receptor, glucagon, and remains an investigational compound studied in clinical trials rather than an approved medicine.
At a glance
| Tirzepatide | Retatrutide | |
|---|---|---|
| What it is | Dual GLP-1/GIP receptor agonist sold as Mounjaro for type 2 diabetes and Zepbound for weight loss | Investigational triple GLP-1/GIP/glucagon receptor agonist studied in clinical trials for weight loss |
| How it's thought to work | Activates both GLP-1 and GIP receptors together, studied for appetite suppression, insulin signaling, and fat metabolism | Activates GLP-1, GIP, and glucagon receptors together, studied for appetite suppression, insulin signaling, and energy expenditure |
| Regulatory status | FDA-approved as Mounjaro for type 2 diabetes and Zepbound for weight loss | Not FDA-approved; investigational, sold outside trials only by unregulated research-chemical suppliers |
| Strength of evidence | Human trials (the SURMOUNT program) and FDA approval | Human trials: a Phase 2 study (Jastreboff et al., NEJM 2023); not yet approved |
| Reported side effects | GI profile similar to semaglutide; injection site reactions; higher hypoglycemia risk when combined with insulin | Nausea (most common), diarrhea, vomiting, constipation, decreased appetite; generally mild to moderate |
| Common vial sizes | 5mg, 10mg, 15mg, 30mg | 5mg, 10mg |
| Mixing math example | 10 mg + 2 mL BAC water = 5,000 mcg/mL, 50 mcg per unit | 5 mg + 1 mL BAC water = 5,000 mcg/mL, 50 mcg per unit |
Key differences
Tirzepatide is a dual GLP-1/GIP receptor agonist. Retatrutide activates a third receptor, glucagon, which research associates with increased energy expenditure and fat oxidation in addition to the appetite and insulin-signaling effects shared with GLP-1 and GIP activation. GIP and GLP-1 are both incretin hormones the gut releases after eating, while glucagon is a separate pancreatic hormone research links to energy use rather than appetite alone.
Tirzepatide is FDA-approved as Mounjaro for type 2 diabetes and Zepbound for weight loss, dispensed as branded prescription products. Retatrutide is not FDA-approved. It is an investigational compound, and outside clinical trials it is sold only by unregulated research-chemical suppliers, with no branded, prescription form of its own.
Reported side effects overlap: nausea, vomiting, diarrhea, and constipation appear with both. Tirzepatide's reported effects also include injection site reactions and a hypoglycemia risk with insulin. Retatrutide's reported effects also include decreased appetite among commonly reported effects, generally described as mild to moderate.
What the research covers
The SURMOUNT trial program tested tirzepatide in humans and reported body weight reduction of up to 22.5%, supporting its FDA approval. Retatrutide's evidence comes from a Phase 2 trial (Jastreboff et al., NEJM 2023), which reported body weight reduction of up to 24.2% at 48 weeks and, in a substudy of participants with MASLD, average liver fat reductions of up to 82% at 24 weeks. Retatrutide's trial program has not yet reached FDA approval.
Frequently asked questions
What is the difference between tirzepatide and retatrutide?
Tirzepatide activates the GLP-1 and GIP receptors and is FDA-approved. Retatrutide activates those two receptors plus glucagon and remains an investigational compound studied in clinical trials.
Is tirzepatide or retatrutide FDA-approved?
Tirzepatide is FDA-approved as Mounjaro and Zepbound. Retatrutide is not FDA-approved; it is still an investigational compound.
Which has more human research, tirzepatide or retatrutide?
Tirzepatide has a completed FDA-reviewed trial program (SURMOUNT). Retatrutide has Phase 2 human trial data (Jastreboff et al., NEJM 2023) but has not completed the approval process.
Can tirzepatide and retatrutide be compared directly?
Only partially. They share GLP-1 and GIP activation, but retatrutide adds glucagon receptor activity and has a different regulatory status, so trial results were measured in separate study populations.
Both entries, plus the calculator
The PeptidesAI app covers Tirzepatide, Retatrutide and 68 other compounds, with a reconstitution calculator, a dose log and reminders. Free to download on iPhone.
Download on the App Store